Results 201 to 210 of about 265,018 (314)
Mutational profiling in acute myeloid leukemia. [PDF]
DiNardo CD.
europepmc +1 more source
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange +16 more
wiley +1 more source
Refining favorable-risk classification in pediatric <i>RUNX1::RUNX1T1</i> acute myeloid leukemia. [PDF]
Zhang X.
europepmc +1 more source
AR expression in AML cells is same in female vs male patients. [PDF]
Taussig DC, Miraki-Moud F.
europepmc +1 more source
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger +13 more
wiley +1 more source
RETRACTED: Li et al. TRIM10 Is Downregulated in Acute Myeloid Leukemia and Plays a Tumor Suppressive Role via Regulating NF-κB Pathway. <i>Cancers</i> 2023, <i>15</i>, 417. [PDF]
Li L, Li Q, Zou Z, Huang Z, Chen Y.
europepmc +1 more source
Cancer Risk in Marfan Syndrome: A Swedish Population‐Based Cohort Study
The cancer risk in Marfan syndrome, an autosomal dominant connective tissue disorder, largely remains to be explored. In this population‐based matched cohort study of 1544 Swedish patients, the overall cancer risk in adults with Marfan syndrome showed no significant increase, except for the risk of endocrine tumours with a nearly threefold increase ...
Ida Nordgren +8 more
wiley +1 more source
Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia. [PDF]
García R +8 more
europepmc +1 more source
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel +26 more
wiley +1 more source

